Potential mechanisms of at1 receptor blockers on reducing pneumonia-related mortality

Clinical Infectious Diseases

Volumn 56, Issue 8, 2013, Pages 1193-1194

  Nahmod, Karen A ^a   Nahmod, Victor E ^b   Szvalb, Ariel D ^c  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR CCR2; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOPEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THROMBOXANE A2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D RECEPTOR;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; BLOOD VESSEL PERMEABILITY; CHEMOTAXIS; CYTOKINE RELEASE; LETTER; LEUKOCYTE; LUNG ALVEOLUS CELL; LUNG CLEARANCE; LUNG INJURY; MORTALITY; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PNEUMONIA;

EID: 84875663817     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit007     Document Type: Letter

References (26)

1. Mortensen EM, Nakashima B, Cornell J, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012; 55:1466-73.
2. Phillips MI, Kagiyama S. Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs 2002; 3:569-77.
3. Sadoshima J. Cytokine actions of angiotensin II. Circ Res 2000; 86:1187-9. (Pubitemid 30436655)
4. Lijnen P, Fagard R, Petrov V. Cytosolic calcium changes induced by angiotensin II in human peripheral blood mononuclear cells are mediated via angiotensin II subtype 1 receptors. J Hypertens 1997; 15:871-6. (Pubitemid 27344851)
5. Nataraj C, Oliverio MI, Mannon RB, et al. Angiotensin II regulates immune responses through a calcineurin-dependent pathway. J Clin Invest 1999; 104:1693-701. (Pubitemid 30053186)
6. Nahmod KA, Vermeulen ME, Raiden S, et al. Control of dendritic cell differentiation by angiotensin II. FASEB J 2003; 17: 491-3.
7. Jurewicz M, McDermott DH, Sechler JM, et al. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 2007; 18:1093-1102. (Pubitemid 46536895)
8. Platten M, Youssef S, Hur EM, et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A 2009; 106: 14948-53.
9. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204:2449-60. (Pubitemid 47529329)
10. Bodor C, Nagy JP, Végh B, et al. Angiotensin II increases the permeability and PV-1 expression of endothelial cells. Am J Physiol Cell Physiol 2012; 302:C267-76.
11. Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009; 325:612-6.
12. Elferink JG, de Koster BM. The stimulation of human neutrophil migration by angiotensin II: its dependence on Ca2+ and the involvement of cyclic GMP. Br J Pharmacol 1997; 121:643-8. (Pubitemid 27260765)
13. El Bekay R, Alvarez M, Monteseirín J, et al. Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-kappaB. Blood 2003; 102:662-71. (Pubitemid 36841990)
14. Kranzhofer R, Browatzki M, Schmidt J, Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 1999; 257: 826-34.
15. Hernandez-Presa M, Bustos C, et al. Angiotensin- converting enzyme inhibition prevents arterial nuclear factor-kB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbitmodel of early accelerated atherosclerosis. Circulation 1997; 95:1532-9.
16. Fernandez-Castelo S, Arzt ES, Pesce A, et al. Angiotensin II regulates interferon-gamma production. J Interferon Res 1987; 7:261-8.
17. Fukuzawa M, Satoh J, Sagara M, et al. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology 1997; 36:49-55. (Pubitemid 27153477)
18. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferatoractivated receptor-gamma activity. Circulation 2004; 109:2054-7. (Pubitemid 38620211)
19. Marshall TG, Lee RE, Marshall FE. Common angiotensin receptor blockers my directly modulate the immune system via VDR, PPAR and CCR2b. Theorl Biol Med Model 2006; 3:1.
20. Raiden S, Giordano M, Andonegui G, et al. Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits the binding of N-formylmethionyl-leucylphenylalanine to neutrophil receptors. J Pharmacol Exp Ther 1997; 281:624-8. (Pubitemid 27203791)
21. Liu EC, Hedberg A, Goldenberg HJ, Harris DNWebb ML. DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors. Prostaglandins 1992; 44:89-99.
22. Raiden S, Pereyra Y, Nahmod V, et al. Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits neutrophil recruitment in the lung triggered by fMLP. J Leukoc Biol 2000; 68:700-6.
23. Raiden S, Nahmod KA, Nahmod VE, et al. Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. J Pharmacol Exp Therap 2002; 303:45-51.
24. Chan YC, Leung PS. AT1 receptor antagonism ameliorates acute pancreatitis-associated pulmonary injury. Regul Pept 2006; 134:46-53.
25. Shen L, Mo H, Cai L, et al. Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock 2009; 31:500-6.
26. Liu L, Qiu HB, Yang Y, Wang L, Ding HM, Li HP. Losartan, an antagonist of AT1 receptor for angiotensin II, attenuates lipopolysaccharide- induced acute lung injury in rat. Arch Biochem Biophys 2009; 481:131-6.